346 related articles for article (PubMed ID: 30601533)
21. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Godugu C; Doddapaneni R; Singh M
Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
Kazi A; Lawrence H; Guida WC; McLaughlin ML; Springett GM; Berndt N; Yip RM; Sebti SM
Cell Cycle; 2009 Jun; 8(12):1940-51. PubMed ID: 19471122
[TBL] [Abstract][Full Text] [Related]
23. Urea-containing peptide boronic acids as potent proteasome inhibitors.
Han LQ; Yuan X; Wu XY; Li RD; Xu B; Cheng Q; Liu ZM; Zhou TY; An HY; Wang X; Cheng TM; Ge ZM; Cui JR; Li RT
Eur J Med Chem; 2017 Jan; 125():925-939. PubMed ID: 27769033
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
25. Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
Liu L; Fu Y; Zheng Y; Ma M; Wang C
Phytomedicine; 2020 Nov; 78():153312. PubMed ID: 32866906
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H
J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687
[TBL] [Abstract][Full Text] [Related]
27. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
Zhang CH; Chen K; Jiao Y; Li LL; Li YP; Zhang RJ; Zheng MW; Zhong L; Huang SZ; Song CL; Lin WT; Yang J; Xiang R; Peng B; Han JH; Lu GW; Wei YQ; Yang SY
J Med Chem; 2016 Nov; 59(21):9788-9805. PubMed ID: 27739679
[TBL] [Abstract][Full Text] [Related]
28. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
29. The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer.
Du Y; Song L; Zhang L; Ling H; Zhang Y; Chen H; Qi H; Shi X; Li Q
Eur J Med Chem; 2017 Aug; 136():457-467. PubMed ID: 28525844
[TBL] [Abstract][Full Text] [Related]
30. Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells.
Ettari R; Pallio G; Pizzino G; Irrera N; Zappalà M; Maiorana S; Di Chio C; Altavilla D; Squadrito F; Bitto A
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1307-1313. PubMed ID: 31307247
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
[TBL] [Abstract][Full Text] [Related]
32. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
Zhao Y; Xu L; Zhang J; Zhang M; Lu J; He R; Xi J; Zhuang R; Li J; Zhou Y
Bioorg Med Chem; 2021 Jan; 29():115867. PubMed ID: 33223460
[TBL] [Abstract][Full Text] [Related]
33. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors.
Han L; Wen Y; Li R; Xu B; Ge Z; Wang X; Cheng T; Cui J; Li R
Bioorg Med Chem; 2017 Aug; 25(15):4031-4044. PubMed ID: 28634039
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.
Agyin JK; Santhamma B; Roy SS
Bioorg Med Chem Lett; 2013 Dec; 23(23):6455-8. PubMed ID: 24119559
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.
Miller Z; Kim KS; Lee DM; Kasam V; Baek SE; Lee KH; Zhang YY; Ao L; Carmony K; Lee NR; Zhou S; Zhao Q; Jang Y; Jeong HY; Zhan CG; Lee W; Kim DE; Kim KB
J Med Chem; 2015 Feb; 58(4):2036-41. PubMed ID: 25658656
[TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
Zhang CH; Zheng MW; Li YP; Lin XD; Huang M; Zhong L; Li GB; Zhang RJ; Lin WT; Jiao Y; Wu XA; Yang J; Xiang R; Chen LJ; Zhao YL; Cheng W; Wei YQ; Yang SY
J Med Chem; 2015 May; 58(9):3957-74. PubMed ID: 25835317
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.
Zhu Y; Zhu X; Wu G; Ma Y; Li Y; Zhao X; Yuan Y; Yang J; Yu S; Shao F; Li R; Ke Y; Lu A; Liu Z; Zhang L
J Med Chem; 2010 Mar; 53(5):1990-9. PubMed ID: 20158184
[TBL] [Abstract][Full Text] [Related]
39. BU-32: a novel proteasome inhibitor for breast cancer.
Agyin JK; Santhamma B; Nair HB; Roy SS; Tekmal RR
Breast Cancer Res; 2009; 11(5):R74. PubMed ID: 19821999
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel pyrimidine molecules containing boronic acid as VCP/p97 Inhibitors.
Zhang Y; Xie X; Wang X; Wen T; Zhao C; Liu H; Zhao B; Zhu Y
Bioorg Med Chem; 2021 May; 38():116114. PubMed ID: 33831696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
